COVID-19 Surveillance in Rural Mozambique for Prompt and Effective Response
NCT ID: NCT05228639
Last Updated: 2023-08-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
6494 participants
OBSERVATIONAL
2020-12-01
2022-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effectiveness Evaluation of the Sinopharm Vaccine in the Dondo District in Mozambique
NCT05362682
Plasmodium Falciparum Genomic Intelligence in Mozambique
NCT05306067
Malaria Molecular Surveillance in Mozambique (Phase 2)
NCT06529237
Effectiveness of Vaccination Against COVID-19 in Brazil: Case-Control Study
NCT05621928
Cost-effectiveness Evaluation of Vector Control Strategies in Mozambique
NCT02910934
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Individuals of any age admitted to MDH or pregnant attending the Maragra health center meet the COVID-19 case definition as defined above after the project start date.
* Resident of Manhiça DSS area
* Written informed consent from a parent or guardian if a child, and from participant if an adult prior recruitment.
2. COVID-19 mortality surveillance • All deaths in children under the age of 5 (including stillbirths), occurring at the health facility or at the community; • In hospital adult deaths occurring at the MDH;
• Resident of Manhiça DSS area;
• Written informed consent from the relative of the dead person.
3. COVID-19 population-based serosurveys • Individuals of all age groups residing in Manhiça DSS surveillance area • Signed informed parental permission from a parent or guardian if a child and from participant if an adult.
4. Natural history of SARS-CoV-2 infection
• Participants who fulfill eligibility criteria for activity a) and with laboratory-confirmed SARS-CoV-2 infection.
5. Clinical presentation and factors associated with SARS-CoV-2 • Participants who fulfill eligibility criteria for activities a) and c).
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Barcelona Institute for Global Health
OTHER
Imperial College London
OTHER
Instituto Nacional de Saúde, Mozambique
OTHER_GOV
Instituto de Biomedina de Valencia, IBV
UNKNOWN
World Health Organization
OTHER
Centro de Investigacao em Saude de Manhica
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centro de investigacao em saude de Manhica
Manhiça, , Mozambique
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
80/CNBS/20
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.